Search results for "Parkinson's disease -- Treatment"

showing 3 items of 3 documents

THE ENTERIC NERVOUS SYSTEM: NEW DEVELOPMENTS AND EMERGING CONCEPTS

2011

The enteric nervous system (ENS) is an integrative neuronal network, organized in two ganglionated plexuses, myenteric and submucosal, composed of neurons and enteric glial cells, controlling the activity of the smooth muscle of the gut, mucosal secretion and blood flow. The ENS contains as many neurons as the spinal cord, and the functional and chemical diversity of enteric neurons closely resembles that of the central nervous system. This highly integrated neural system is also referred to as the ‘brain-in-the-gut’, because of its capability to function in the absence of nerve inputs from the central nervous system.

Gastrointestinal system -- Innervation -- Physiologynervous systemGastrointestinal system -- InnervationParkinson’s diseaseParkinson's disease -- TreatmentneurotransmissionEnteric nervous systemEnteric nervous system; neurotransmission; Parkinson’s disease
researchProduct

Non-steroidal anti-inflammatory drugs in Parkinson’s disease

2007

Parkinson's disease (PD) is known to be a chronic and progressive neurodegenerative disease caused by a selective degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc). A large body of experimental evidence indicates that the factors involved in the pathogenesis of this disease are several, occurring inside and outside the DAergic neuron. Recently, the role of the neuron–glia interaction and the inflammatory process, in particular, has been the object of intense study by the research community. It seems to represent a new therapeutic approach opportunity for this neurological disorder. Indeed, it has been demonstrated that the cyclooxygenase type 2 (COX-…

Parkinson's diseaseSubstantia nigraParkinson's DeseaseNeuroprotectionSettore BIO/09 - FisiologiaCyclooxygenase inhibitorschemistry.chemical_compoundDevelopmental NeuroscienceDopamineMedicineHumansNervous system -- DiseasesAgedInflammationHydroxydopaminebusiness.industryPars compactaMPTPDopaminergicAnti-Inflammatory Agents Non-SteroidalParkinson DiseaseParkinson's disease -- TreatmentMiddle Agedmedicine.diseaseNeuroprotective AgentsNeurologychemistrynervous systembusinessNeuroscienceNervous system -- Degenerationmedicine.drug
researchProduct

Will it ever become possible to prevent dopaminergic neuronal degeneration?

2008

Parkinsons disease (PD) is the second leading age-related degenerative brain disease in the world affecting millions of people. This neurological disorder disrupts the quality of life of patients and their families, exerts an enormous emotional and physical strain on caregivers, and has a large cost for society. Moreover, the increasing numbers of elderly people in the population will result in a sharp increase in the prevalence of PD. The understanding of its pathophysiology and treatment has advanced at a very impressive rate during past decades. Nevertheless, PD is still fatal and there is at present no cure for it. Furthermore, there are no proven therapies for prevention of PD and alth…

medicine.medical_specialtyDopaminePopulationNeurological disorderDiseaseNeuroprotectionSettore BIO/09 - FisiologiaNeuroprotective agentsRisk FactorsmedicineAnimalsHumansNeuronal degenerationNeurodegeneration Neuroprotection Parkinson's diseaseIntensive care medicineeducationPharmacologyNeuronseducation.field_of_studyCell Deathbusiness.industryGeneral NeuroscienceDopaminergicNeurodegenerative DiseasesParkinson's disease -- Treatmentmedicine.diseaseBrain diseaseNeuroprotective AgentsDrug developmentbusinessNervous system -- Degeneration
researchProduct